Granules India Reports Strong FY26, Q4 PAT Jumps 33% to Rs 2,016 Mn
New Delhi: Granules India Limited has reported strong financial performance for the quarter and financial year ended March 31, 2026, with Q4 FY26 revenue rising 23% year-on-year to Rs 14,706 million, EBITDA increasing 40% to Rs 3,521 million, profit before tax (PBT) before exceptional items up 48% to Rs 2,464 million, and profit after tax (PAT) growing 33% to Rs 2,016 million, while full-year FY26 revenue stood at Rs 53,656 million (up 20%), EBITDA at Rs 11,851 million (up 25%), and PAT at Rs 5,950 million (up 19%).
The company’s quarterly EBITDA margin improved to 24% compared to 21% in the same period last year, while PAT margin stood at 14%. On an annual basis, EBITDA margin improved to 22% from 21% in FY25, with net profit margin remaining stable at 11%.
Region-wise, North America contributed 72% of Q4FY26 revenue compared to 79% in Q4FY25, while Europe’s share increased significantly to 17% from 8% in the previous year, indicating a diversification in geographic revenue mix.
In terms of segment contribution, finished dosages (FD) accounted for 73% of revenue, followed by APIs at 13%, pharmaceutical formulation intermediates (PFI) at 9%, and peptides/CDMO at 5%. The company also reported improved capital efficiency, with return on capital employed (ROCE) rising to 17.6% in FY26 from 16.6% in FY25, alongside a reduction in net debt to ₹4,021 million and a net debt to EBITDA ratio of 0.34x.
Commenting on the performance, Chairman and Managing Director Dr. Krishna Prasad Chigurupati stated that the company delivered strong results driven by portfolio expansion, disciplined execution, and continued progress in regulatory, compliance, and sustainability initiatives, along with steady advancement in complex generics and the peptides CDMO platform.
